Sensorium Therapeutics Highlights Promising Data on Lead Assets Targeting Anxiety & Epilepsy at Neuroscience 2024
illi News/10280908

Trending...
BOSTON, Oct. 10, 2024 ~ Chicago, IL - Sensorium Therapeutics, a biotechnology company focused on developing innovative medicines for central nervous system (CNS) diseases, presented positive preclinical data on their lead programs at Neuroscience 2024. The company also shared details on the capabilities of its Biodynamic Discovery Platform™ at the conference held this week in Chicago.

The preclinical data presented at the conference highlighted the potential of Sensorium's unique drug discovery strategy. This approach combines medicinal chemistry, advanced neuronal screening models, and machine learning to develop novel first-in-class CNS medicines inspired by natural compounds and supported by proven human efficacy and safety data.

"We are excited to share these promising results that validate our de-risked drug development approach," said Alexandra Glucksmann, PhD, CEO of Sensorium. "These findings further demonstrate the potential of our platform to deliver breakthrough CNS medicines as we prepare to enter clinical trials next year."

The company's lead programs, SENS-01 and SENS-03, were the focus of the presentation. SENS-01 is a novel highly selective fast-acting anxiolytic for the treatment of anxiety disorders. It is a synthetic derivative of a natural compound with proven human validation as a fast onset anxiolytic. The molecule has shown excellent CNS drug-like properties with a clean safety profile and in vivo efficacy in multiple models. Currently completing IND-enabling studies, SENS-01 is expected to enter clinical trials in early 2025.

More on illi News
SENS-03 is another promising program being developed by Sensorium. It is a novel chemical entity with a differentiated mechanism of action to address focal onset seizures in drug-resistant epilepsy patients. This program also has potential to address comorbid anxiety, which affects 80% of patients with drug-resistant epilepsy. Preclinical data has shown efficacy in multiple validated seizure models as well as preclinical anxiety models.

Sensorium's Biodynamic Discovery Platform™ was also highlighted at the conference. This platform utilizes an advanced and comprehensive integrated ethnopharmacological knowledge graph to discover molecules with proven human efficacy. Novel cellular models, including human iPSC-derived and rodent primary neural systems, are used to define differentiation and novel pharmacology for compounds. This data provides valuable insights for advancing novel drug candidates.

"We are proud of the progress we have made with our Biodynamic Discovery Platform™," said Jeffrey Brown, PhD, Chief Scientific Officer at Sensorium. "It has allowed us to identify and advance a novel therapeutic for the treatment of epilepsy with comorbid anxiety, as well as other potential treatments for CNS diseases."

More on illi News
The company's poster presentations at Neuroscience 2024 included details on SNTX-AXN, a novel fast-acting anxiolytic discovered and developed from Sensorium's AI-driven product engine. The presentation highlighted the molecule's differentiated pharmacology from standard of care and its proven efficacy in both in vitro and in vivo studies.

Another poster presentation focused on Sensorium's SENS-AI Platform, which identified a natural compound with human validation for both anxiolytic and anti-epileptic properties. Chemical optimization of this compound led to novel synthetic derivatives that maintain its efficacy while improving its CNS-drug like properties.

In addition, Sensorium presented data on their Discovery Platform for Phenotypic Characterization of Natural Products in IPSC-Derived and Primary Neuronal Models. This platform has been instrumental in advancing novel drug classifiers and providing mechanistic insight for compounds currently being developed by the company.

Overall, the positive preclinical data presented by Sensorium at Neuroscience 2024 highlights the potential of their unique drug discovery approach to deliver much-needed treatments for CNS diseases. With plans to enter clinical trials next year, the company is well-positioned to make significant contributions to this field.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on illi News